drugset / Trial / NCT01145755
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD2066 | Small molecule | 18 mg | — |
| Comparator | Duloxetine | Small molecule | 60 mg | — |